0001479290-24-000103.txt : 20240702 0001479290-24-000103.hdr.sgml : 20240702 20240702174703 ACCESSION NUMBER: 0001479290-24-000103 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schilke Tobin CENTRAL INDEX KEY: 0001678984 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 241097362 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, #371 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wk-form4_1719956817.xml FORM 4 X0508 4 2024-06-30 0 0001479290 Revance Therapeutics, Inc. RVNC 0001678984 Schilke Tobin C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 0 1 0 0 CFO 0 Common Stock 2024-06-30 5 A 0 E 1000 2.1845 A 193666 D These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). /s/ Dwight Moxie, Attorney-in-Fact 2024-07-02